 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CUPERTINO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ( Reviva or the Company ), a late-stage pharmaceutical company developing therapies that...

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

CUPERTINO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ( Reviva or the Company ), a late-stage pharmaceutical company developing therapies that...

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Key Insights Significant control over Reviva Pharmaceuticals Holdings by retail investors implies that the general...

Retail investors among Reviva Pharmaceuticals Holdings, Inc.'s (NASDAQ:RVPH) largest stockholders and were hit after last week's 34% price drop

CUPERTINO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ( Reviva or the Company ), a late-stage pharmaceutical company developing therapies that...

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Brilaroxazine's Positive Trial Outcomes Amidst Increased Net LossRelated Stocks: RVPH...

Reviva Pharmaceuticals Holdings Inc Reports Q3 2023 Financial Results

- RECOVER global Phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with...

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH  Free Report)  Analysts at HC Wainwright boosted their Q4 2023 EPS estimates for Reviva Pharmaceuticals in a report released on...

HC Wainwright Research Analysts Raise Earnings Estimates for Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)

- Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total...

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

In trading on Monday, drugs shares were relative leaders, up on the day by about 2.5%. Leading the group were shares of Reviva Pharmaceuticals Holdings, up about 64.9% and shares of Deciphera...

Video: Monday Sector Leaders: Drugs, Education & Training Services

This is a signal that RVPH's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Reviva Pharmaceuticals Holdings (RVPH, $3.71) RSI Indicator left the oversold zone on October 19, 2023

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

Watchers	2,637
52-Wk Low	$3.03
52-Wk High	$9.25

Market Cap	$106.93M
Volume (M)	229,615.00
52-Wk High	$9.25
52-Wk Low	$3.03

Current Price	$3.84
Prev Close	$3.83
Open	$3.99
Dividend Yield	0.00%
50-Day Moving Average	$4.66
Beta	0.72
Avg. Volume	679,392.24
PE Ratio	-2.27

52-Week High	$9.25
52-Week Low	$3.03
Market Capitalization	$106.93M
EPS	-$1.69
Price to Book	-9.30
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-3.02

RVPH Reviva Pharmaceuticals Holdings Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals